Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Design and Implementation of a National SARS-CoV-2 Monitoring Program in England: REACT-1 Study.

Elliott P., Whitaker M., Tang D., Eales O., Steyn N., Bodinier B., Wang H., Elliott J., Atchison C., Ashby D., Barclay W., Taylor G., Darzi A., Cooke GS., Ward H., Donnelly CA., Riley S., Chadeau-Hyam M.

Data System. The REal-time Assessment of Community Transmission-1 (REACT-1) Study was funded by the Department of Health and Social Care in England to provide reliable and timely estimates of prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection over time, by person and place. Data Collection/Processing. The study team (researchers from Imperial College London and its logistics partner Ipsos) wrote to named individuals aged 5 years and older in random cross-sections of the population of England, using the National Health Service list of patients registered with a general practitioner (near-universal coverage) as a sampling frame. We collected data over 2 to 3 weeks approximately every month across 19 rounds of data collection from May 1, 2020, to March 31, 2022. Data Analysis/Dissemination. We have disseminated the data and study materials widely via the study Web site, preprints, publications in peer-reviewed journals, and the media. We make available data tabulations, suitably anonymized to protect participant confidentiality, on request to the study's data access committee. Public Health Implications. The study provided inter alia real-time data on SARS-CoV-2 prevalence over time, by area, and by sociodemographic variables; estimates of vaccine effectiveness; and symptom profiles, and detected emergence of new variants based on viral genome sequencing. (Am J Public Health. 2023;113(5):545-554. https://doi.org/10.2105/AJPH.2023.307230).

More information Original publication

DOI

10.2105/ajph.2023.307230

Type

Journal article

Publication Date

2023-05-01T00:00:00+00:00

Volume

113

Pages

545 - 554

Total pages

9

Addresses

P, a, u, l, , E, l, l, i, o, t, t, ,, , M, a, t, t, h, e, w, , W, h, i, t, a, k, e, r, ,, , D, a, v, i, d, , T, a, n, g, ,, , O, l, i, v, e, r, , E, a, l, e, s, ,, , B, a, r, b, a, r, a, , B, o, d, i, n, i, e, r, ,, , H, a, o, w, e, i, , W, a, n, g, ,, , C, h, r, i, s, t, i, n, a, , A, t, c, h, i, s, o, n, ,, , D, e, b, o, r, a, h, , A, s, h, b, y, ,, , H, e, l, e, n, , W, a, r, d, ,, , a, n, d, , M, a, r, c, , C, h, a, d, e, u, -, H, y, a, m, , a, r, e, , w, i, t, h, , t, h, e, , S, c, h, o, o, l, , o, f, , P, u, b, l, i, c, , H, e, a, l, t, h, ,, , I, m, p, e, r, i, a, l, , C, o, l, l, e, g, e, , L, o, n, d, o, n, ,, , U, K, ., , N, i, c, h, o, l, a, s, , S, t, e, y, n, , a, n, d, , C, h, r, i, s, t, l, , A, ., , D, o, n, n, e, l, l, y, , a, r, e, , w, i, t, h, , t, h, e, , D, e, p, a, r, t, m, e, n, t, , o, f, , S, t, a, t, i, s, t, i, c, s, ,, , U, n, i, v, e, r, s, i, t, y, , o, f, , O, x, f, o, r, d, ,, , O, x, f, o, r, d, ,, , U, K, ., , J, o, s, h, u, a, , E, l, l, i, o, t, t, , i, s, , w, i, t, h, , t, h, e, , I, m, p, e, r, i, a, l, , C, o, l, l, e, g, e, , H, e, a, l, t, h, c, a, r, e, , N, H, S, , T, r, u, s, t, ,, , L, o, n, d, o, n, ., , A, r, a, , D, a, r, z, i, , i, s, , w, i, t, h, , t, h, e, , I, n, s, t, i, t, u, t, e, , o, f, , G, l, o, b, a, l, , H, e, a, l, t, h, , I, n, n, o, v, a, t, i, o, n, ,, , I, m, p, e, r, i, a, l, , C, o, l, l, e, g, e, , L, o, n, d, o, n, ., , W, e, n, d, y, , B, a, r, c, l, a, y, ,, , G, r, a, h, a, m, , T, a, y, l, o, r, ,, , a, n, d, , G, r, a, h, a, m, , S, ., , C, o, o, k, e, , a, r, e, , w, i, t, h, , t, h, e, , D, e, p, a, r, t, m, e, n, t, , o, f, , I, n, f, e, c, t, i, o, u, s, , D, i, s, e, a, s, e, ,, , I, m, p, e, r, i, a, l, , C, o, l, l, e, g, e, , L, o, n, d, o, n, .

Keywords

Humans, Cross-Sectional Studies, Public Health, State Medicine, England, COVID-19, SARS-CoV-2